Description
Patient Access to Care Director, UK&I
The position
The Patient Access to Care (PAC) Director role is a commercial leadership position within the Liver & Acute Anti-infectives (AAI) BU and is responsible for leading Gilead’s non-promotional patient finding ‘Elimination Initiatives’ across UK and Ireland. Reporting to the Senior Business Unit Director, Liver & AAI, you’ll be responsible for Gilead’s cross-functional HCV patient finding strategy as well as accountable for elimination initiatives within Addiction services.
In England, Gilead has established partnerships with the majority of providers of Addiction services providing funding to enable the deployment of HCV coordinators and data analysts across these settings. Working with NHS England’s Operational Delivery Networks (ODNs) our collective aim is to ensure that every individual in these settings is tested and treated via a patient pathway that works for them.
In Wales, Ireland and Scotland, we are working with the National Programs to align and leverage Gilead’s patient finding expertise to complement the national initiatives and to identify areas of unmet need.
You’ll be leading a high-performing, experienced team of field-based PAC managers that has won numerous HSJ awards, delivered micro-elimination in 52 sites and treated > 10,000 individuals.
You’ll thrive in this role if you:
enjoy leading through ambiguity and change management are a dynamic, strategic thinker with a focus on measurable impact bring the right people together, set a collective ambition and work with a range of different stakeholders to achieve it have the highest integrity and judgement of risk you are driven by the mission and can inspire others to act
This role is a unique opportunity in your career; to contribute daily towards England being the first major country in the world to eliminate this virus; to work with the NHS and charities to drive change from within the system; and to evolve our patient finding beyond HCV into other disease areas within the BU.
Specific Responsibilities:
Develop and execute cross-functional Patient-finding strategy across UK&I to achieve target of number of patients commencing DAA treatment Manage Provider initiatives to achieve expected outcomes, deploying budget to unlock additional impact or expedite progress, whilst ensuring initiatives have patient care at their heart Ensure Gilead demonstrably acts as a true partner with NHSE and the ODNs, and meet tender obligations Lead, develop and equip PAC team, ensuring effective measurement and supporting tools/materials Inspire external stakeholders to act in pursuit of elimination as well keeping internal momentum locally and Globally Ensure clear focus on compliance with industry regulations, legal requirements and internal business conduct policies in this sensitive and potentially complex area. As a member of the BU leadership team, actively contribute to the effective operation of the wider business unit, leading and supporting key initiatives
Knowledge, Experience and Skills:
Experience of patient pathway optimisation from diagnosis to treatment is an advantage, particularly in HCV Proven success leading and developing a team within a performance-driven environment Demonstrated ability to develop strategy and measure impact in a complex environment, execute with excellence and course correct as required Excellent cross-functional leadership – include and mobilise others to maximize their contribution to deliver the strategy Excellent internal and external stakeholder management – create productive relationships with a wide range of stakeholders being viewed as a valued partner. Strong understanding of industry code of conduct and key relevant legislation. Articulate and compelling communicator Experience in external partnering and commercial relationships highly valued Demonstrated ability to ruthlessly prioritise and deliver with impact
Additional background
Most recent estimates (2022) suggest that around 62,600 people in England are living with chronic Hepatitis C infection (HCV). HCV is a curable infection, and the UK Government has committed to eliminating the disease ahead of the WHO ambition of 2030. In the UK, injecting drug use continues to be the single largest risk factor for HCV infection, so testing is increasingly being undertaken in settings where those individuals are likely to be, such as in Addiction services, community pharmacies, homeless shelters, prisons and other healthcare settings.
To support HCV Elimination, NHSE have worked with Pharmaceutical companies to establish an ‘Elimination framework’ whereby NHSE procures both medicines and Elimination initiatives.
Gilead was awarded Gold status in that framework and since May 2019 has been working with partners to support HCV elimination.
Equal Employment Opportunity (EEO)
It is the policy of Gilead Sciences, Inc. and its subsidiaries and affiliates (collectively "Gilead" or the "Company") to recruit select and employ the most qualified persons available for positions throughout the Company. Except if otherwise provided by applicable law, all employment actions relating to issues such as compensation, benefits, transfers, layoffs, returns from layoffs, company-sponsored training, education assistance, social and recreational programs are administered on a non-discriminatory basis (i.e. without regard to protected characteristics or prohibited grounds, which may include an individual’s gender, race, color, national origin, ancestry, religion, creed, physical or mental disability, marital status, sexual orientation, medical condition, veteran status, and age, unless such protection is prohibited by federal, state, municipal, provincial, local or other applicable laws). Gilead also prohibits discrimination based on any other characteristics protected by applicable laws.
For Current Gilead Employees and Contractors:
Please log onto your to apply for this job.
